首页> 外文OA文献 >PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)

【2h】

PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)

机译：厄洛替尼一线治疗弱势老年患者晚期非小细胞肺癌（NSCLC）一线治疗的PCN79成本效益：一项前瞻性2期研究的经济分析（GFPC 0505）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Chouaid C.; Le Caer H.; Corre R.; Crequit J.; Jullian H.; Falchero L.; Dujon C.; Vergnenegre A.;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505) [J] . ChouaidC., LeCaerH., CorreR., Clinical lung cancer . 2013,第2期

机译：厄洛替尼与化疗对参加前瞻性2期研究的年老体弱患者的非小细胞肺癌一线治疗的成本分析（GFPC 0505）
2. A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study) [J] . LeCaerH., GreillierL., CorreR., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第1期

机译：吉西他滨联合厄洛替尼的多中心II期随机试验在进展中而非相反，用于通过综合老年病评估选择的晚期非小细胞肺癌弱势老年患者（GFPC 0505研究）
3. Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group [J] . Hervé Le Caer, Isabelle Borget, Romain Corre, Journal of Thoracic Disease . 2017,第10期

机译：全面的老年医学评估对老年晚期非小细胞肺癌（NSCLC）患者的管理的预后作用：GFPC集团对两项前瞻性II期试验的汇总分析
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of ontario, canada [D] . Thao, Mallory. 2014

机译：加拿大安大略省非小细胞肺癌患者早期肺癌筛查的成本效益及分子亚群的检测和治疗
6. Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504) [O] . Chouaid Christos, Le Caer Hervé, Locher Chrystelle, 2012

机译：厄洛替尼与化学疗法在参加前瞻性2期研究的健康老年患者中一线治疗非小细胞肺癌（NSCLC）的成本效益（GFPC 0504）
7. PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504) [O] . Chouaid C, Lecaer H, Crequit J, 2010

机译：厄洛替尼在晚期老年非小细胞肺癌（NSCLC）一线治疗的一线治疗中的PCN84成本效益：预期的第2阶段研究的经济分析（GFPC 0504）

PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)

著录项

引文网络

相似文献

相关主题

期刊订阅